Product Description
a CAR-T adaptor molecule (CAM)-based therapy that uses a bispecific small-molecule ligand EC17, fluorescein isothiocyanate (FITC) conjugated with folic acid, to redirect FITC-specific CAR-T cells against folate receptor (FR)-positive tumors. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433934/)
Mechanisms of Action: FR1 Contrast Agent
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Centre for Human Drug Research
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Ovarian Cancer|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma
Phase 1: Renal Cell Carcinoma|Breast Cancer|Hyperparathyroidism, Primary|Ovarian Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2013-004089-33 | P2 |
Completed |
Ovarian Cancer|Non-Small-Cell Lung Cancer |
2015-04-01 |
|
| 818533 [UPenn IRB Protocol #] | P1 |
Completed |
Ovarian Cancer |
2014-11-12 |
|
| EC17 | P1 |
Completed |
Breast Cancer |
2014-11-01 |
|
| 818060 [UPenn IRB Protocol] | P1 |
Completed |
Hyperparathyroidism, Primary |
2014-09-01 |